Gaylussacin (1), a stilbene glucoside, has been isolated from Pentarhizidium orientale and is used in Korean folk medicine. Although it was first isolated in 1972, the synthesis of gaylussacin has never been reported. Herein, we report the first total synthesis of gaylussacin in six steps with an overall yield of 23.8%, as well as the synthesis of its derivatives. Structurally, gaylussacin contains a carboxylic acid and a glycoside along with a free phenol on the same benzene ring, making selective functionalization for the synthesis of 1 difficult. Heck cross-coupling was employed as a key step to introduce the stilbene moiety. Glycosylation followed by global deprotection provided natural product 1.

No abstract

No abstract

Metastatic triple-negative breast cancer (mTNBC) is a fatal type of breast cancer (BC), and signal transducer and activator of transcription 3 (STAT3) has emerged as an effective target for mTNBC. In the present study, compound MC0704 was found to be a novel synthetic STAT3 pathway inhibitor, and its potential antitumor activity was demonstrated using in vitro and in vivo models in docetaxel-resistant TNBC cells. Based on marinacarboline (MC), a series β-carboline derivatives were synthesized and investigated for their antitumor activities against docetaxel-resistant MDA-MB-231 (MDA-MB-231-DTR) cells. Combining antiproliferation and STAT3 inhibitory activities, MC0704 was selected as the most promising βcarboline compound. MC0704 effectively impeded the metastatic potential of MDA-MB-231-DTR cells in vitro, and the combination of MC0704 and docetaxel exhibited potent antitumor activities in a xenograft mouse model. These findings suggested that MC0704 can be a lead candidate as a target therapeutic agent for TNBC patients with docetaxel resistance.

No abstract